CCR1 activation contributes to the BBB damage associated with a variety of neuroinflammatory diseases, including multiple sclerosis (MS), diabetes mellitus, and Alzheimer’s disease [11, 12]. This evidence concerns the gene CCR1 and early-onset autosomal dominant Alzheimer disease.